Company Overview and News

 
Flinders Mines’ Canegrass vanadium estimates lowered

2018-01-31 australianmining.com.au
Flinders Mines, the explorer responsible for the 700-square-kilometre Canegrass vanadium project in Western Australia, has lowered its project estimates after commissioning industry consultants to provide Canegrass for JORC 2012 compliance documentation.

 
Flinders Mines iron ore mine sustains minor damage during bushfire that tore through Western Australia’s Pilbara

2017-11-15 perthnow.com.au
SOUTH Australian mineral resources company Flinders Mines has reopened its Pilbara iron ore operations four days after a bushfire forced the evacuation of the camp.

 
Flinders chasing $16m

2017-05-09 businessnews.com.au
Flinders Mines is seeking to raise $16 million to advance its Pilbara iron ore project, with the company needing to fund further work to progress the mine to feasibility stage.

1
Cobalt 27 Announces New Board, Offering of Shares and Agreements to Acquire Physical Cobalt and Cobalt-Related Royalties

2017-04-24 marketwired
Cobalt 27 Capital Corp. (TSX VENTURE: KBLT) (the "Company" or "Cobalt 27") announces that it has entered into a number of contracts and arrangements which in aggregate constitute a "change of business" under TSX Venture Exchange Policy 5.2. Specifically, the Company:

 
Todd Corporation poised to announce $5.26b iron ore project in Western Australia

2017-01-23 nzherald.co.nz
The Todd Corporation has signed a deal with the West Australian government that could lead to a $5.9 billion iron ore project in the state.

 
Flinders Mines' shares placed in trading halt

2017-01-22 proactiveinvestors.com.au
Details are pending regarding the port and rail infrastructure development of the Balla Balla Infrastructure Group (BBIG).

 
Flinders Mines Ltd kicks off $5M rights issue

2016-10-07 proactiveinvestors.com.au
Flinders Mines Ltd (ASX:FMS) will undertake a 1:10 rights issue which will offer up to circa 295 million shares priced at $0.017 to raise $5 million. The offer price represents a discount of 32% to the 30-day volume weighted average price of Flinders shares. Shareholders of the company as of the record date of 12 October, 2016 will be able to participate in the offer. The offer opens on Monday, 17 October and closes Friday, 4 November.

 
Flinders in $5m raising

2016-10-07 businessnews.com.au
South Australian mining junior Flinders Mines has announced a capital raising of $5 million, with the company to put the cash towards a loan repayment and tenement expenditure commitments at its Pilbara iron ore project.

 
Flinders Mines Ltd kicks off $5M rights issue

2016-10-06 proactiveinvestors.com.au
Flinders Mines Ltd (ASX:FMS) will undertake a 1:10 rights issue which will offer up to circa 295 million shares priced at $0.017 to raise $5 million. The offer price represents a discount of 32% to the 30-day volume weighted average price of Flinders shares. Shareholders of the company as of the record date of 12 October, 2016 will be able to participate in the offer. The offer opens on Monday, 17 October and closes Friday, 4 November.

 
Ex-limo firm, Kiwi billionaire bet on iron ore with projects, mine takeovers

2016-09-27 theage.com.au
The global iron ore market is awash with supply and prices remain volatile, but a former Chinese limousine rental service and a billionaire New Zealand family are among producers and developers wagering that new mines will be needed.

 
Ex-limo firm, Kiwi billionaire bet on iron ore with projects, mine takeovers

2016-09-27 smh.com.au
The global iron ore market is awash with supply and prices remain volatile, but a former Chinese limousine rental service and a billionaire New Zealand family are among producers and developers wagering that new mines will be needed.

 
Resource Sector Digest: Another One Bites The Dust

2016-08-28 seekingalpha
Click to enlargeIf you thought the US leading the tally of the Rio Olympics was an achievement to be proud of, then make sure to also consider the achievement of America's very own latest World Champion.

 
Supplementary Target's Statement

2016-05-12 asx.com.au

 
Change in substantial holding

2016-05-11 asx.com.au

 
Change in substantial holding

2016-05-10 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

16h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...